Literature DB >> 17512092

Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.

Christin Andersson1, Kaj Blennow, Ove Almkvist, Niels Andreasen, Peter Engfeldt, Sven-Erik Johansson, Maria Lindau, Maria Eriksdotter-Jönhagen.   

Abstract

BACKGROUND: Little is known about longitudinal changes of cerebrospinal fluid (CSF) biomarkers during cognitive decline in neurodegenerative disease progression.
OBJECTIVE: To investigate longitudinal changes in CSF biomarkers--total-tau (T-tau), phospho-tau (P-tau) and beta-amyloid (Abeta42)--during cognitive decline.
METHODS: Forty memory clinic patients (47.5% females), aged 61.3+/-7.6 (S.D.) years, non-demented at baseline, underwent lumbar puncture and neuropsychological testing at two occasions. Baseline mean MMSE-score was 28.3+/-1.8. Patients were divided into three groups based on baseline memory functioning; severely impaired (SIM), moderately impaired (MIM) and no impairment (NIM).
RESULTS: There was a significant increase in P-tau in the SIM-group during follow-up, while P-tau in MIM and NIM did not change. Eighty-three percent of the SIM-patients converted to dementia (80% AD), while most MIM- and NIM-patients remained non-demented. T-tau- and Abeta42-levels did not change in any of the memory groups during follow-up.
CONCLUSION: Increasing P-tau levels during cognitive decline and conversion to dementia suggest that P-tau may be useful as a longitudinal marker of the neurodegenerative process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512092     DOI: 10.1016/j.neurobiolaging.2007.03.027

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  23 in total

1.  CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

Authors:  Norbert Zilka; Miroslava Korenova; Branislav Kovacech; Khalid Iqbal; Michal Novak
Journal:  Acta Neuropathol       Date:  2010-04-09       Impact factor: 17.088

2.  Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data.

Authors:  W M Van Der Flier; P Scheltens
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 3.  Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment.

Authors:  P J Visser
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

4.  Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Authors:  Yuetiva Deming; Zeran Li; Manav Kapoor; Oscar Harari; Jorge L Del-Aguila; Kathleen Black; David Carrell; Yefei Cai; Maria Victoria Fernandez; John Budde; Shengmei Ma; Benjamin Saef; Bill Howells; Kuan-Lin Huang; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Sungeun Kim; Andrew J Saykin; Philip L De Jager; Marilyn Albert; Abhay Moghekar; Richard O'Brien; Matthias Riemenschneider; Ronald C Petersen; Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Vivianna M Van Deerlin; Virginia Man-Yee Lee; Leslie M Shaw; John Q Trojanowski; Gerard Schellenberg; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Elaine R Peskind; Ge Li; Antonio F Di Narzo; John S K Kauwe; Alison M Goate; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2017-02-28       Impact factor: 17.088

5.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD.

Authors:  P Vemuri; H J Wiste; S D Weigand; D S Knopman; J Q Trojanowski; L M Shaw; M A Bernstein; P S Aisen; M Weiner; R C Petersen; C R Jack
Journal:  Neurology       Date:  2010-07-13       Impact factor: 9.910

6.  Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type.

Authors:  Lei Wang; Anne M Fagan; Aarti R Shah; Mirza Faisal Beg; John G Csernansky; John C Morris; David M Holtzman
Journal:  Alzheimer Dis Assoc Disord       Date:  2012 Oct-Dec       Impact factor: 2.703

7.  Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy.

Authors:  Yu Wang; Aneeka M Hancock; Joshua Bradner; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Karen L Edwards; Katherine W Snapinn; David S Goldstein; Min Shi; Jing Zhang
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

8.  Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.

Authors:  Alex E Roher; Chera L Maarouf; Lucia I Sue; Yiran Hu; Jeffrey Wilson; Thomas G Beach
Journal:  Biomarkers       Date:  2009-11       Impact factor: 2.658

9.  Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease.

Authors:  Marie-Odile Habert; Leonardo Cruz de Souza; Foudil Lamari; Nelle Daragon; Serge Desarnaud; Claude Jardel; Bruno Dubois; Marie Sarazin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

10.  Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.

Authors:  David Peterson; Caitlin Munger; Jared Crowley; Chris Corcoran; Carlos Cruchaga; Alison M Goate; Maria C Norton; Robert C Green; Ronald G Munger; John C S Breitner; Kathleen A Welsh-Bohmer; Constantine Lyketsos; Joann Tschanz; John S K Kauwe
Journal:  Alzheimers Dement       Date:  2013-05-30       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.